These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 717408)
1. Audit of the de Haen Drugs-In-Use Drug Information System. Grove WR; Lamy PP; Fortner CL Am J Hosp Pharm; 1978 Dec; 35(12):1523-4. PubMed ID: 717408 [TBL] [Abstract][Full Text] [Related]
2. Errors in the de Haen Drugs-in-Use Drug Information System. Conner CS Am J Hosp Pharm; 1979 Apr; 36(4):448, 152. PubMed ID: 433932 [No Abstract] [Full Text] [Related]
3. Content and accuracy of abstracting services: clinical perspective. Michel DJ Hosp Formul; 1988 Jul; 23(7):596-8, 601-3, 607. PubMed ID: 10288149 [TBL] [Abstract][Full Text] [Related]
4. Comparative content evaluation of the de Haen and Drugdex drug information systems. Rosenberg JM; Fuentes RJ; Kirschenbaum HL; Dolinsky D Am J Hosp Pharm; 1983 Oct; 40(10):1664-9. PubMed ID: 6638030 [TBL] [Abstract][Full Text] [Related]
5. Modifications in the Paul de Haen Drug Information System. Groth PE Am J Hosp Pharm; 1979 Jun; 36(6):745. PubMed ID: 463889 [No Abstract] [Full Text] [Related]
6. An exercise in the use of the secondary literature: introduction to the use of the de Haen Drugs in Use and Drugs in Research systems. Hicks CI Am J Pharm Educ; 1975 Aug; 39(3):318-9. PubMed ID: 10237132 [No Abstract] [Full Text] [Related]
7. An evaluation of 'Inpharma', a drug literature abstracting service. Milne A J Clin Hosp Pharm; 1981 Sep; 6(3):189-93. PubMed ID: 7298861 [TBL] [Abstract][Full Text] [Related]
8. Adverse drug effects: evaluation of four secondary reference sources. Lyon RA Hosp Formul; 1985 Mar; 20(3):315-7, 320-1. PubMed ID: 10270307 [TBL] [Abstract][Full Text] [Related]
9. Advantages of a universal coding and classification system for drugs. Structure of classifications and codes in the De Haen Drug Index Cards. Savitz GS Am J Hosp Pharm; 1966 Feb; 23(2):92-5. PubMed ID: 5907118 [No Abstract] [Full Text] [Related]
10. Evaluation of three manual drug information retrieval systems for investigational antineoplastic drugs. Al Hefzi A; Catania PN; Mergener MA; Lum BL Drug Intell Clin Pharm; 1987 Feb; 21(2):196-200. PubMed ID: 3829913 [TBL] [Abstract][Full Text] [Related]
11. Information--the key to the future. de Haen P Drug Inf J; 1979; 13(3-4):130-4. PubMed ID: 10247918 [No Abstract] [Full Text] [Related]
12. Scope, completeness, and accuracy of drug information in Wikipedia. Clauson KA; Polen HH; Boulos MN; Dzenowagis JH Ann Pharmacother; 2008 Dec; 42(12):1814-21. PubMed ID: 19017825 [TBL] [Abstract][Full Text] [Related]
14. Newer aspects of national poison control information system with emphasis on drugs. Armstrong G Drug Inf J; 1975; 9(2-3):168-70. PubMed ID: 10236971 [No Abstract] [Full Text] [Related]
15. [Development and testing of a pilot information system for pharmacotherapy on the basis of linked data banks of pharmaceutical products and biomedical literature]. Rosenkranz KO; Unger GE Methods Inf Med Suppl; 1978; 11():425-39. PubMed ID: 279773 [No Abstract] [Full Text] [Related]
16. Indexing and abstracting services to the primary drug literature. Illsley SS; Sudds TW Hosp Formul; 1982 Sep; 17(9):1193-7. PubMed ID: 10257545 [No Abstract] [Full Text] [Related]
17. Reviewing current literature--imperative in providing clinical services. Stein ZL Am J Hosp Pharm; 1980 Apr; 37(4):468, 470. PubMed ID: 7377207 [No Abstract] [Full Text] [Related]
18. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. Rohra DK; Gilani AH; Memon IK; Perven G; Khan MT; Zafar H; Kumar R J Pharm Pharm Sci; 2006; 9(1):50-9. PubMed ID: 16849008 [TBL] [Abstract][Full Text] [Related]
19. A quality assurance audit of a drug information service. Johnson N; Dupuis LL Can J Hosp Pharm; 1989 Apr; 42(2):57-61. PubMed ID: 10292922 [TBL] [Abstract][Full Text] [Related]